Jingrong Jean Cui Sells 11,500 Shares of Turning Point Therapeutics (NASDAQ:TPTX) Stock

Turning Point Therapeutics (NASDAQ:TPTX) insider Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $52.94, for a total value of $608,810.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jingrong Jean Cui also recently made the following trade(s):

  • On Monday, December 9th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $55.32, for a total transaction of $636,180.00.
  • On Thursday, December 5th, Jingrong Jean Cui sold 56,110 shares of Turning Point Therapeutics stock. The shares were sold at an average price of $51.95, for a total transaction of $2,914,914.50.

TPTX stock opened at $55.40 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 36.64 and a current ratio of 36.64. The company’s 50 day moving average is $48.31 and its 200 day moving average is $43.08. Turning Point Therapeutics has a 1-year low of $24.21 and a 1-year high of $58.56.

Turning Point Therapeutics (NASDAQ:TPTX) last announced its earnings results on Monday, November 4th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.04). Research analysts forecast that Turning Point Therapeutics will post -3.08 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Turning Point Therapeutics during the 2nd quarter valued at $25,000. Rhumbline Advisers grew its position in Turning Point Therapeutics by 15.7% in the third quarter. Rhumbline Advisers now owns 6,729 shares of the company’s stock worth $253,000 after acquiring an additional 911 shares in the last quarter. Wells Fargo & Company MN purchased a new position in Turning Point Therapeutics in the second quarter worth $72,000. JPMorgan Chase & Co. bought a new position in Turning Point Therapeutics in the second quarter valued at $71,000. Finally, Cubist Systematic Strategies LLC bought a new position in Turning Point Therapeutics in the second quarter valued at $90,000. 66.79% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Turning Point Therapeutics in a research note on Tuesday. Wedbush started coverage on shares of Turning Point Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $63.00 target price on the stock. Roth Capital began coverage on shares of Turning Point Therapeutics in a report on Thursday, November 14th. They issued a “buy” rating and a $65.00 price target for the company. Zacks Investment Research upgraded shares of Turning Point Therapeutics from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a research report on Friday, November 8th. Finally, Wells Fargo & Co upped their price target on shares of Turning Point Therapeutics from $53.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Eleven equities research analysts have rated the stock with a buy rating, Turning Point Therapeutics currently has an average rating of “Buy” and an average target price of $55.00.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Recommended Story: What is a price target?

Insider Buying and Selling by Quarter for Turning Point Therapeutics (NASDAQ:TPTX)

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit